Wellgistics Health Explores $105 Million Acquisition of Neuritek Therapeutics
New York, Monday, 23 March 2026.
On March 23, 2026, Wellgistics Health announced a $105 million potential acquisition of Neuritek Therapeutics, targeting the integration of a groundbreaking root-cause PTSD treatment into its expanding healthcare platform.
Strategic Expansion Beyond Pharmacy Distribution
Following a press release dated March 22, 2026, Wellgistics Health, Inc. (NASDAQ:WGRX) formally announced on Monday, March 23, 2026, its exploration of a potential $105 million all-stock acquisition of Neuritek Therapeutics [1][2]. This proposed transaction represents a concerted effort by Wellgistics to broaden its healthcare platform, moving strategically beyond its core technology-enabled pharmacy distribution and services [1]. By potentially integrating a research-focused organization into its corporate structure, the company anticipates creating a stronger alignment between the initial stages of drug development and eventual market commercialization [1].
Targeting the Root Cause of Psychiatric Disorders
The acquisition target, Neuritek Therapeutics, Inc., was founded by Dr. William Hapworth, MD, and focuses on pioneering innovative therapies for psychiatric and neurological conditions [1]. The cornerstone of Neuritek’s research portfolio is a next-generation, bio-mechanism-based treatment specifically engineered to address the root cause of Post-Traumatic Stress Disorder (PTSD) [1]. Standard treatments for PTSD often focus heavily on symptom management rather than underlying biological causes, making Neuritek’s causal approach a potentially significant disruptor in the psychiatric pharmaceutical market [GPT].
Broader Corporate Strategy and Future Outlook
The potential absorption of Neuritek Therapeutics does not appear to be an isolated maneuver for Wellgistics Health. The company has explicitly stated that it is currently evaluating a wider array of strategic opportunities across both the healthcare and life science sectors [1]. These ongoing evaluations include the prospect of additional acquisitions and strategic partnerships, signaling a robust period of intended corporate growth and consolidation [1]. As the March 2026 LOI progresses through the due diligence phase, the broader market will be watching to see if Wellgistics can successfully transition from a distribution-centric model to a vertically integrated healthcare and biopharmaceutical entity [1][GPT].